MedTrace Logo

A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease

NCT01322594 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2013-10-23

Study results available
· View outcomes & findings →

Summary

Phase I study to evaluate the safety and tolerability of single ascending intravenous doses of MEDI2338 in subjects with stable, mild to moderate chronic obstructive pulmonary disease (COPD).

Conditions

Interventions

BIOLOGICAL

MEDI2338

MEDI2338 single intravenous (IV) dose (lowest dose)

BIOLOGICAL

MEDI2338

MEDI2338 single IV dose (next highest dose)

BIOLOGICAL

MEDI2338

MEDI2338 single IV dose (next highest dose)

BIOLOGICAL

MEDI2338

MEDI2338 single IV dose (next highest dose)

BIOLOGICAL

MEDI2338

MEDI2338 single IV dose (highest dose)

OTHER

Placebo

Placebo single IV dose

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • Edward Piper, MBBS · MedImmune Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-11-30
Completion
2011-12-31

Countries

  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01322594 on ClinicalTrials.gov